Cover Image
市場調查報告書

急性骨髓灰白質炎 (小兒麻庳) :開發中產品分析

Poliomyelitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362372
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
急性骨髓灰白質炎 (小兒麻庳) :開發中產品分析 Poliomyelitis - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 85 Pages
簡介

本報告提供急性骨髓灰白質炎 (小兒麻庳) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

急性骨髓灰白質炎 (小兒麻庳)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

急性骨髓灰白質炎 (小兒麻庳) :企業開發中的治療藥

急性骨髓灰白質炎 (小兒麻庳) :大學/機關研究中的治療藥

急性骨髓灰白質炎 (小兒麻庳) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

急性骨髓灰白質炎 (小兒麻庳) :企業開發中的產品

急性骨髓灰白質炎 (小兒麻庳) :大學/機關研究中的產品

急性骨髓灰白質炎 (小兒麻庳)的治療藥的開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Bilthoven Biologicals B.V.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • Codagenix, Inc.
  • 第一三共
  • Grifols, S.A.
  • Johnson & Johnson
  • LG Life Science LTD.
  • Nanolek, LLC
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • Taiga Biotechnologies, Inc.

急性骨髓灰白質炎 (小兒麻庳) :治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

急性骨髓灰白質炎 (小兒麻庳) :最近的開發平台趨勢

急性骨髓灰白質炎 (小兒麻庳) :暫停中的計劃

急性骨髓灰白質炎 (小兒麻庳) :開發中止的產品

急性骨髓灰白質炎 (小兒麻庳) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8824IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poliomyelitis Overview
  • Therapeutics Development
  • Pipeline Products for Poliomyelitis - Overview
    • Pipeline Products for Poliomyelitis - Comparative Analysis
    • Poliomyelitis - Therapeutics under Development by Companies
    • Poliomyelitis - Therapeutics under Investigation by Universities/Institutes
  • Poliomyelitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Poliomyelitis - Products under Development by Companies
  • Poliomyelitis - Products under Investigation by Universities/Institutes
  • Poliomyelitis - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Beijing Tiantan Biological Products Co Ltd
    • Bharat Biotech International Ltd
    • Biken Inc
    • Bilthoven Biologicals BV
    • Biological E Ltd
    • Boryung Pharmaceutical Co Ltd
    • Codagenix Inc
    • Daiichi Sankyo Company Ltd
    • GlaxoSmithKline Plc
    • Grifols SA
    • Johnson & Johnson
    • Kaketsuken KK
    • LG Life Science LTD
    • Nanolek
    • Panacea Biotec Ltd
    • Sanofi Pasteur SA
    • Sentinext Therapeutics Sdn Bhd
    • Shantha Biotechnics Ltd
    • Taiga Biotechnologies Inc
    • Takeda Pharmaceutical Company Ltd
  • Poliomyelitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ImmunoRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPVGVI-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio (virus like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio [strain Sabin] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poliomyelitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Poliomyelitis - Dormant Projects
  • Poliomyelitis - Discontinued Products
  • Poliomyelitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Poliomyelitis, H2 2016
  • Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016
  • Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016
  • Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H2 2016
  • Poliomyelitis - Pipeline by Biken Inc, H2 2016
  • Poliomyelitis - Pipeline by Bilthoven Biologicals BV, H2 2016
  • Poliomyelitis - Pipeline by Biological E Ltd, H2 2016
  • Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
  • Poliomyelitis - Pipeline by Codagenix Inc, H2 2016
  • Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Poliomyelitis - Pipeline by Grifols SA, H2 2016
  • Poliomyelitis - Pipeline by Johnson & Johnson, H2 2016
  • Poliomyelitis - Pipeline by Kaketsuken KK, H2 2016
  • Poliomyelitis - Pipeline by LG Life Science LTD, H2 2016
  • Poliomyelitis - Pipeline by Nanolek, H2 2016
  • Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2 2016
  • Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2 2016
  • Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016
  • Poliomyelitis - Pipeline by Shantha Biotechnics Ltd, H2 2016
  • Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H2 2016
  • Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Poliomyelitis - Dormant Projects, H2 2016
  • Poliomyelitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Poliomyelitis, H2 2016
  • Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top